GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Other Stockholders Equity

Aclaris Therapeutics (FRA:8AT) Other Stockholders Equity : €-0.00 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Other Stockholders Equity?

Aclaris Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2024 was €-0.00 Mil.

Aclaris Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then declined from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€-0.00 Mil).

Aclaris Therapeutics's annual Other Stockholders Equity increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€0.00 Mil) and increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Aclaris Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Aclaris Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Other Stockholders Equity Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aclaris Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aclaris Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Aclaris Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics (FRA:8AT) Business Description

Traded in Other Exchanges
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines